BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN10597 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN10597\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06787612-11314@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:REGN10597: Phase 2 readout est. (NCT06787612)
DESCRIPTION:REGN10597\, phase 2.\nStudy: Investigation of Ubamatamab Combin
 ation Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
 \nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/regn10597#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/regn10597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-11314@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:REGN10597: Phase 2 readout est. (NCT06465329)
DESCRIPTION:REGN10597\, phase 2.\nStudy: A Study of Cemiplimab Plus Chemoth
 erapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for
  Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)\nEstimate
 d primary completion: 4 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/regn10597#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/regn10597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413680-11314@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:REGN10597: Phase 1/2 readout est. (NCT06413680)
DESCRIPTION:REGN10597\, phase 1/2\, Advanced Solid Tumors.\nStudy: A First-
 In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone o
 r in Combination With Cemiplimab Works in Adult Participants Who Have Canc
 er With Tumors That Have Spread in Their Body\nEstimated primary completio
 n: 3 February 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 egn10597#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06413680
URL:https://assetmemo.bio/drug/regn10597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
